<DOC>
	<DOC>NCT00950742</DOC>
	<brief_summary>Study to determine the Maximum Tolerated dose of BIBW 2992 given in combination with Herceptin速</brief_summary>
	<brief_title>Phase I Open Label Trial to Assess Safety of BIBW 2992 (Afatinib) in Combination With Herceptin速 in Patients With HER2-positive Advanced Breast Cancer.</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Inclusion criteria: 1. Female patients aged &gt;18 years. 2. Advanced or metastatic breast cancer that overexpresses HER2 (immunohistochemistry 3+ or 2+ and gene amplification by FISH). Prior treatment with Herceptin速 or Lapatinib速 (in the adjuvant or metastatic settings) is permitted but not required. Exclusion criteria: Patients with untreated or symptomatic brain metastases. Prior treatment with EGFR targeting therapies or treatment with EGFR or HER2 inhibiting drugs within the past four weeks before the start of therapy or concomitantly with this study.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>